Full text
Earnings transcript
Read the complete earnings call transcript.
CNC
Centene Corp.
$65.89
0.42
(0.64%)
| Exchange: | NYSE |
| Market Cap: | 32.549B |
| Shares Outstanding: | 10.811M |
Delayed data
About The Company
| Sector: | Healthcare | |||||
| Industry: | Medical – Healthcare Plans | |||||
| CEO: | Sarah McGinty London | |||||
| Full Time Employees: | 61100 | |||||
| Address: |
| |||||
| Website: | https://www.centene.com |
Centene Corporation operates as a managed care company that provides programs and services to under-insured families, and commercial organizations in the United States. It operates through four segments: Medicaid, Medicare, Commercial, and Other. The Medicaid segment offers the temporary assistance for needy families; medicaid expansion; aged, blind, or disabled; and children’s health insurance programs, as well as long-term services and supports; foster care; and medicare-medicaid plans. This segment also provides healthcare products and services. The Medicare segment offers special needs and medicare supplement, and prescription drug plans. The Commercial segment provides health insurance marketplace product for individual and commercial group. The Other segment operates clinical healthcare and pharmacies, as well as offers vision and dental, behavioral health, and centralized services. It provides services through primary and specialty care physicians, hospitals, behavioral health practitioners, and ancillary providers. The company was founded in 1984 and is headquartered in Saint Louis, Missouri.
Click to read more…
Revenue Segmentation
EPS
Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.
Earnings Call
AI summary
Key takeaways
Short, structured highlights from the call so you can focus on what matters.
Log in to continue
Log in to read the full transcript and AI-generated earnings summaries.
Login — it's freeIncome Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 153,999,000 | 163,071,000 | 194,777,000 |
| Gross Profit | 17,315,000 | 16,829,000 | 23,833,439 |
| EBITDA | 5,616,000 | 6,200,000 | -5,140,375 |
| Operating Income | 2,930,000 | 3,175,000 | -7,618,375 |
| Net Income | 2,702,000 | 3,305,000 | -6,673,000 |
(* All numbers are in thousands)
Balance Sheet
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Total Assets | 84,641,000 | 82,445,000 | 76,747,000 |
| Total Liabilities | 58,685,000 | 55,935,000 | 56,691,000 |
| Total Stockholders Equity | 25,840,000 | 26,410,000 | 19,953,000 |
| Total Debt | 18,877,000 | 19,429,000 | 17,401,000 |
| Cash and Cash Equivalents | 17,193,000 | 14,063,000 | 17,888,000 |
(* All numbers are in thousands)
Cash Flow Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating Cash Flow | 8,053,000 | 154,000 | 5,088,000 |
| Capital Expenditure | -799,000 | -644,000 | -767,000 |
| Free Cash Flow | 7,254,000 | -490,000 | 4,321,000 |
| Net Income | 2,702,000 | 3,294,000 | -6,677,000 |
| Net Change in Cash | 5,122,000 | -3,296,000 | 3,801,000 |
(* All numbers are in thousands)
Analyst Estimates
| Fiscal Year | 2030 | Research Access | Research Access | Research Access | Research Access |
|---|---|---|---|---|---|
| Estimated Revenue (Low) | 211,980,497.114 | Research Access | Research Access | Research Access | Research Access |
| Estimated Revenue (High) | 222,144,501.311 | Research Access | Research Access | Research Access | Research Access |
| Estimated Revenue (Avg) | 216,886,000 | Research Access | Research Access | Research Access | Research Access |
| Estimated Ebitda (Low) | 4,512,517.123 | Research Access | Research Access | Research Access | Research Access |
| Estimated Ebitda (High) | 4,728,882.513 | Research Access | Research Access | Research Access | Research Access |
| Estimated Ebitda (Avg) | 4,616,942.606 | Research Access | Research Access | Research Access | Research Access |
| Estimated Net Income (Low) | 4,315,900.260 | Research Access | Research Access | Research Access | Research Access |
| Estimated Net Income (High) | 4,586,804.488 | Research Access | Research Access | Research Access | Research Access |
| Estimated Net Income (Avg) | 4,446,647.914 | Research Access | Research Access | Research Access | Research Access |
| Estimated SGA Expense (Low) | 16,199,466.678 | Research Access | Research Access | Research Access | Research Access |
| Estimated SGA Expense (High) | 16,976,195.903 | Research Access | Research Access | Research Access | Research Access |
| Estimated SGA Expense (Avg) | 16,574,343.290 | Research Access | Research Access | Research Access | Research Access |
| Estimated EPS (Avg) | 9.060 | Research Access | Research Access | Research Access | Research Access |
| Estimated EPS (High) | 9.340 | Research Access | Research Access | Research Access | Research Access |
| Estimated EPS (Low) | 8.790 | Research Access | Research Access | Research Access | Research Access |
| Number of Analysts (Estimated Revenue) | 6 | Research Access | Research Access | Research Access | Research Access |
| Number of Analysts (Estimated EPS) | 1 | Research Access | Research Access | Research Access | Research Access |
Log in to continue
Log in and subscribe to Full Access to see up to 5 years of analyst estimates.
Login — it's free(* All numbers are in thousands)
Current Key Metrics
Log in to continue
Log in to see all key valuation metrics and ratios for this symbol.
Login — it's freeForward P/E Ratios
Log in to continue
Log in with Full Access for forward P/E high/low estimates and the full multi-year table.
Login — it's freeSWOT Analysis
Strengths (preview)
- Robust Revenue Performance: CNC has demonstrated consistent revenue growth as reported in recent income statements, reflecting strong operational efficiency and market demand for its offerings within the sector.
- Healthy Cash Flow Metrics: The company exhibits strong free cash flow yield (as per key metrics TTM), indicating solid liquidity and the ability to fund operations, investments, and potential dividend payouts without straining finances.
- Favorable Valuation Metrics: CNC's current price-to-earnings ratio (P/E TTM) and forward P/E ratios suggest the stock is reasonably valued compared to industry averages, providing a stable investment profile for value-focused investors.
- Strong Balance Sheet: High levels of cash and cash equivalents, coupled with manageable debt-to-equity ratios (as per balance sheet data), position CNC with financial flexibility to weather economic downturns or invest in growth initiatives.
Log in with Research Access for Weaknesses, Opportunities, Threats, and the complete SWOT.
At what price to buy it? -
Intrinsic Value Calculator
This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.
[intrinsic_calculator]
Common questions about CNC valuation
Is Centene Corp. (CNC) overvalued or undervalued right now?
MARKETSnap estimates intrinsic value for Centene Corp. (CNC) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.
Is CNC a buy, hold, or sell for long-term investors?
MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether CNC trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.
What is CNC’s P/E ratio?
You can see CNC’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.
How is intrinsic value calculated for CNC?
MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.
Is CNC a good long-term investment?
Whether CNC fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.
CNC
1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.
Daily snapshot
0.64
Trading Metrics:
| Open: | 64.97 | Previous Close: | 65.47 | |
| Day Low: | 64.75 | Day High: | 66.09 | |
| Year Low: | 28.24 | Year High: | 69.36 | |
| Price Avg 50: | 65.04 | Price Avg 200: | 49.29 | |
| Volume: | 827080 | Average Volume: | 5.44M |
Log in to continue
Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.
Login — it's freeCNC full analysis
Welcome to MARKETSNAP’s SWOT analysis for Centene Corporation, also known by its ticker CNC. If you’re a long-term investor looking to build wealth through smart stock picks, you’re in the right place. Today, we’re diving deep into Centene, a major player in the healthcare sector, to break down its strengths, weaknesses, opportunities, and threats. I’ll also sprinkle in some recent news, performance trends, and financial insights to keep things interesting. Let’s get started with a quick overview of who Centene…
